Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: In vitro-in vivo correlations

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 1, 2003, Pages 88-101

  Visser, S A G ^a,d   Wolters, F L C ^a   Gubbens Stibbe, J M ^a   Tukker, E ^a   Van Der Graaf, P H ^b   Peletier, L A ^c   Danhof, Meindert ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c LEIDEN UNIVERSITY   (Netherlands)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

21 CHLORO 3ALPHA HYDROXY 2BETA MORPHOLINO 5ALPHA PREGNAN 20 ONE METHANESULFONATE; 2BETA (2,2 DIMETHYLMORPHOLINO) 3ALPHA HYDROXY 5ALPHA PREGNANE 11,20 DIONE; 2BETA 3ALPHA 5ALPHA 21 CHLORO 3 HYDROXY 2 (4 MORPHOLINYL)PREGNAN 20 ONE; 2BETA 3ALPHA 5ALPHA 3 HYDROXY 2 (2,2 DIMETHYLMORPHOLIN 4 YL)PREGNAN 11,20 DIONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; ALFAXALONE; BENZODIAZEPINE DERIVATIVE; BRETAZENIL; CLOBAZAM; DIAZEPAM; ELTANOLONE; FLUMAZENIL; FLUNITRAZEPAM; GABAERGIC RECEPTOR AFFECTING AGENT; MIDAZOLAM; OXAZEPAM; STEROID; UNCLASSIFIED DRUG; ZOLPIDEM; ZOPICLONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ELECTROENCEPHALOGRAM; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STIMULUS RESPONSE;

ALGORITHMS; ANIMALS; BENZODIAZEPINES; CARBOLINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONVULSANTS; ELECTROENCEPHALOGRAPHY; GABA AGONISTS; GABA MODULATORS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN BINDING; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, GABA-A; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0037216664     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.042341     Document Type: Article

References (41)

1. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Control 19:716-723.
2. A receptors. J Med Chem 40:1668-1681.
3. Arendt RM, Greenblatt DJ, Liebisch DC, Luu MD, and Paul SM (1987) Determinants of benzodiazepine brain uptake: Lipophilicity versus binding affinity. Psychopharmacology 93:72-76.
4. Berrueta LA, Gallo B, and Vicente F (1992) Biopharmacological data and highperformance liquid chromatographic analysis of 1,4-benzodiazepines in biological fluids: A review. J Pharm Biomed Anal 10:109-136.
5. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B 220:141-162.
6. Cleton A, Mazee D, Voskuyl RA, and Danhof M (1999) Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats. Br J Pharmacol 127:227-235.
7. A receptor activity by alphaxalone. Br J Pharmacol 90:491-500.
8. Cox EH, Kerbusch T, Van der Graaf PH, and Danhof M (1998) Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: Correlation with the interaction at the μ-opioid receptor. J Pharmacol Exp Ther 284:1095-1103.
9. Danhof M and Mandema JW (1992) Modelling of the pharmacodynamics and pharmacodynamic interactions of CNS active drugs. Int J Clin Pharmacol Ther Toxicol 30:516-519.
10. Dawson RM and Poretski M (1989) Inhibition constants and GABA-shifts at 2°C and 37°C for a spectrum ofligands acting on the benzodiazepine receptors of guinea pig hippocampus. Gen Pharmacol 20:843-848.
11. Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, and Bartholini G (1986) Zolpidem, a novel non-benzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237:649-658.
12. Facklam M, Schoch P, Bonetti EP, Jenck F, Martin JR, Moreau JL, and Haefely WE (1992) Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther 261:1113-1121.
13. Foster RT, Caille G, Ngoc AH, Lemko CH, Kherani R, and Pasutto FM (1994) Stereospecific high-performance liquid chromatographic assay of zopiclone in human plasma. J Chromatogr B Biomed Appl 658:161-166.
14. Gibaldi M and Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York.
15. Goggin T, Coates L, Gray E, Nave S, Zell M, and Steimer J-L (2000) Integrated pharmacokinetics and pharmacodynamics of a new benzodiazepine in comparison with alprazolam. J Clin Pharmacol 56:879.
16. Greenblatt DJ, Arendt RM, Abernethy DR, Giles HG, Sellers EM, and Shader RI (1983) In vitro quantitation of benzodiazepine lipophilicity: Relation to in vivo distribution. Br J Anaesth 55:985-989.
17. Hoogerkamp A, Arends RH, Bomers AM, Mandema JW, Voskuyl RA, and Danhof M (1996) Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect. J Pharmacol Exp Ther 279:803-812.
18. Kemp JA, Marshall GR, Wong EH, and Woodruff GN (1987) The affinities, potencies and efficacies of some benzodiazepine-receptor agonists, antagonists and inverseagonists at rat hippocampal GABAA-receptors. Br J Pharmacol 91:601-608.
19. Kenakin T (1997) Drug receptor theory, in Pharmacological Analysis of Drug-Receptor Interaction, pp 1-42, Lippincott-Raven, New York.
20. Lambert JJ, Belelli D, Hill Venning C, and Peters JA (1995) Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 16:295-303.
21. Laurijssens BE and Greenblatt DJ (1996) Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 30:52-76.
22. Mandema JW, Kuck MT, and Danhof M (1992) In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. J Pharmacol Exp Ther 261:56-61.
23. Mandema JW, Sansom LN, Dios-Vieitez MC, Hollander-Jansen M, and Danhof M (1991b) Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 257:472-478.
24. Mandema JW, Tukker E, and Danhof M (1991a) Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: Influence of rate and route of administration. Br J Pharmacol 102:663-668.
25. Massotti M, Lucantoni D, Caporali MG, Mele L, and Gatta F (1985) Supraspinal convulsions induced by inverse benzodiazepine agonists in rabbits. J Pharmacol Exp Ther 234:274-279.
26. Mawa R, Mis D, Gagnieu MC, Grancher D, Petit-Ramel M, Bressolle F, and Vallon JJ (1996) Simple high-performance liquid chromatographic separation of oxazepam and its diastereoisomeric glucuronides in serum. Applications in a pharmacokinetic study in sheep. J Chromatogr B Biomed Appl 677:331-338.
27. McCauley LD, Liu V, Chen JS, Hawkinson JE, Lan NC, and Gee KW (1995) Selective actions of certain neuroactive pregnanediols at the gamma-aminobutyric acid type A receptor complex in rat brain. Mol Pharmacol 47:354-362.
28. Mehta AK and Shank RP (1995) Interaction of abecarnil, bretazenil and RO 19-8022 with diazepam-sensitive and -insensitive benzodiazepine sites in the rat cerebellum and cerebral cortex. Life Sci 57:2215-2222.
29. Petersen EN, Jensen LH, Honore T, Braestrup C, Kehr W, Stephens DN, Wachtel H, Seidelman D, and Schmiechen R (1984) ZK 91296, a partial agonist at benzodiazepine receptors. Psychopharmacology 83:240-248.
30. Schoemaker RC and Cohen AF (1996) Estimating impossible curves using NONMEM. Br J Clin Pharmacol 42:283-290.
31. A receptor channel expressed in Xenopus oocytes. J Neurosci 8:289-295.
32. Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, and Danhof M (1999) Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: Midazolam and alpha-OH-midazolam. J Pharmacol Exp Ther 289:1067-1074.
33. Ueki S, Watanabe S, Yamamoto T, Kataoka Y, Shibata S, Shibata K, Ohta H, Shimazoe T, and Kawamoto H (1987) Behavioral and electroencephalographic effects of zopiclone, a cyclopyrrolone derivative. Jpn J Pharmacol 43:309-326.
34. Van der Graaf PH and Danhof M (1997) Analysis of drug-receptor interactions in vivo: A new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther 35:442-446.
35. Van der Graaf PH, Van Schaick EA, Mathot RA, IJzerman AP, and Danhof M (1997) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: Estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther 283:809-816.
36. Van der Graaf PH, Van Schaick EA, Visser SAG, De Greef HJ, IJzerman AP, and Danhof M (1999) Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: Prediction of tissue-dependent efficacy in vivo. J Pharmacol Exp Ther 290:702-709.
37. Van Rijn CM, Willems B, Zwart JP, Rodrigues-de-Miranda JF, and Dirksen R (1999) A molecular model for the synergic interaction between gamma-amino-butyric acid and general anaesthetics. Eur J Pharmacol 371:213-226.
38. A receptor in vivo. J Pharmacol Exp Ther 303:616-626.
39. Visser SAG, Smulders CJGM, Reijers BPR, Van der Graaf PH, Peletier LA, and Danhof M (2002b) Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration dependent hysteresis and biphasic EEG effects of alphaxalone in rats. J Pharmacol Exp Ther 302:1158-1167.
40. Wood PL, Loo P, Braunwalder A, Yokoyama N, and Cheney DL (1983) In vitro characterization of benzodiazepine receptor agonists, antagonists, inverse agonists and agonist/antagonists. J Pharmacol Exp Ther 231:572-576.
41. Zuideveld KP, Maas HJ, Treijtel N, Hulshof J, Van der Graaf PH, Peletier LA, and Danhof M (2001) A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. Am J Physiol Regul Integr Comp Physiol 281:R2059-R2071.